CTLA4 and metastatic melanoma: In another clinical study by Ribas et al.31, the uptake of the cell proliferation tracer [18F]FLT in the spleen was significantly increased in patients with metastatic melanoma upon immunotherapy with the CTLA4-blocking antibody tremelimumab, regardless of therapy response.